Released August 19, 2019 | SUGAR LAND
en
The European Union's Pharmaceutical & Biotech Industry expects to see about 129 projects begin construction in the fourth quarter, with a total value of about $1.85 billion.
Among the highest-valued are Merck's addition to a vaccines and biologics fill and finish facility; BASF SE's addition to an active pharmaceutical ingredient (API) plant; and Regensburg University's addition to a research complex.
Click here for a list, and see chart below for a breakdown by country.
Among the highest-valued are Merck's addition to a vaccines and biologics fill and finish facility; BASF SE's addition to an active pharmaceutical ingredient (API) plant; and Regensburg University's addition to a research complex.
Click here for a list, and see chart below for a breakdown by country.
